Scilex Holding Co reported continued development and commercialization of its non-opioid pain management products but faces substantial liquidity constraints as reflected in a current ratio of 0.08, raising concerns about its ability to sustain operations without additional funding. The company’s portfolio includes FDA-approved products targeting neuropathic pain, migraine, and gout, supported by a sales force focused on managed care formulary access. Its cryptocurrency treasury strategy introduces an unconventional element to its balance sheet but also regulatory risk. Core growth depends on advancing late-stage clinical candidates while managing reimbursement and pricing pressures in a competitive specialty pharmaceutical market.